Cryptococcosis Flashcards

1
Q

What is the most common cause of HIV-associated cryptococcal infections?

A

Cryptococcus neoformans

Occasionally, Cryptococcus gattii may also be a cause.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Where is Cryptococcus gattii most often found?

A

Australia and similar subtropical regions, and in the U.S. Pacific Northwest.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What percentage of people with advanced HIV had disseminated cryptococcosis before effective antiretroviral therapy (ART)?

A

5% to 8%.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How many cases of cryptococcal infection in people with AIDS occur worldwide each year?

A

Approximately 280,000 cases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What percentage of AIDS-related deaths is accounted for by cryptococcal disease?

A

15%.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What CD4 T lymphocyte cell count is associated with 90% of cryptococcal cases in people with HIV?

A

CD4 counts <100 cells/mm3.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are common clinical manifestations of cryptococcosis in people with HIV?

A

Subacute meningitis or meningoencephalitis with fever, malaise, and headache.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the median duration for the development of symptoms in cryptococcosis?

A

2 weeks.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

True or False: Classic meningeal symptoms occur in most people with cryptococcosis.

A

False.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are some encephalopathic symptoms associated with cryptococcosis?

A
  • Lethargy
  • Altered mentation
  • Personality changes
  • Memory loss.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How can isolated pulmonary infection from cryptococcosis present?

A

Cough and dyspnea with abnormal chest radiograph.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What does analysis of cerebrospinal fluid (CSF) usually show in cryptococcosis?

A
  • Mildly elevated protein levels
  • Low-to-normal glucose concentrations
  • Variable pleocytosis.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the significance of a positive cryptococcal antigen (CrAg) test?

A

It indicates the presence of cryptococcal infection.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the preferred method for detecting cryptococcal disease?

A

Culture, CSF microscopy, cryptococcal antigen detection, or CSF polymerase chain reaction (PCR).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the sensitivity of the BioFire FilmArray Meningitis/Encephalitis Panel PCR assay?

A

It performs well in infections with a moderate-to-high fungal burden.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the three methods for antigen detection in cryptococcosis?

A
  • Latex agglutination
  • Enzyme immunoassay (EIA)
  • Lateral flow assay (LFA).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What should be done if a patient with HIV has a negative CSF PCR?

A

Perform CrAg testing of CSF and blood simultaneously.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the recommended action for patients with HIV and CD4 counts ≤200 cells/mm3?

A

Routine surveillance testing for serum CrAg.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What prophylactic treatment can reduce the frequency of primary cryptococcal disease?

A

Fluconazole or itraconazole.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the duration of induction therapy for treating cryptococcosis?

A

2 weeks.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the preferred regimen for induction therapy in the United States?

A

Liposomal amphotericin B 3–4 mg/kg IV once daily plus flucytosine 25 mg/kg PO four times a day.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the duration for consolidation therapy after induction therapy?

A

At least 8 weeks.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the preferred regimen for maintenance therapy?

A

Fluconazole 200 mg PO once daily for ≥1 year.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the criterion for stopping maintenance therapy?

A

At least 1 year from initiation of antifungal therapy and CD4 count ≥100 cells/mm3.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What are the alternative regimens for treating cryptococcosis?

A
  • Amphotericin B lipid complex 5 mg/kg IV daily
  • Itraconazole 200 mg PO twice a day.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What should be done if a patient’s CD4 count declines to <100 cells/mm3?

A

Restart maintenance therapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What is the recommended treatment for Non-CNS extrapulmonary disease with cryptococcal antigenemia?

A

Administer the same treatment as for cryptococcal meningitis

This includes cases with normal CSF and serum CrAg titer ≥1:640 by LFA (or ≥1:160 by EIA or latex agglutination) (BIII)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What is the treatment for Non-CNS focal pulmonary infiltrates with mild symptoms and negative serum CrAg?

A

Fluconazole 400 mg daily for 6 to 12 months

Duration is guided by symptom resolution (BIII)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What is the treatment regimen for isolated asymptomatic cryptococcal antigenemia with serum CrAg titer <1:640?

A

Fluconazole 800–1,200 mg PO daily for 2 weeks, followed by fluconazole 400–800 mg PO daily for 10 weeks, then 200 mg PO daily for a total of 6 months plus effective ART (BIII)

Lower risk patients with serum CrAg titer <1:80 by LFA can be treated without lumbar puncture (AI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What is the preferred therapy for cryptococcal disease during the first trimester of pregnancy?

A

Amphotericin B deoxycholate 0.7–1.0 mg/kg IV daily or lipid formulation amphotericin B 3–4 mg/kg IV daily (AIII)

Flucytosine addition should be considered only when benefits outweigh risks, ideally delayed until after the first trimester (AIII)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What are the three phases of treatment for CNS and disseminated cryptococcal disease?

A

Induction, consolidation, and maintenance

Each phase has specific treatment protocols and monitoring requirements.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What is the recommended induction therapy for cryptococcal meningitis in resource-available settings?

A

Amphotericin B formulation IV plus oral flucytosine for 2 weeks (AII)

Lipid formulations are preferred due to lower toxicity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What is the recommended induction therapy in resource-limited health care settings?

A

Single dose of liposomal amphotericin B (10 mg/kg) followed by 2 weeks of flucytosine and fluconazole (AI)

This regimen aims for effective treatment with fewer resources.

34
Q

What monitoring is required during induction therapy for cryptococcal meningitis?

A

Patients must be monitored in the hospital for at least 7 days and ideally 14 days (AII)

Lumbar punctures should be performed on Day 7 and Day 14.

35
Q

What is the recommended consolidation therapy after successful induction therapy?

A

Fluconazole 800 mg daily for at least 8 weeks (AII)

This is to prevent breakthrough infections during consolidation.

36
Q

What should be done if a patient shows no clinical improvement after 2 weeks of induction therapy?

A

Continue or start amphotericin B plus flucytosine until CSF fungal cultures are confirmed negative (BIII)

This ensures effective treatment is maintained.

37
Q

What alternatives can be used for consolidation therapy if fluconazole is not available?

A

Itraconazole 200 mg twice per day (CI)

Itraconazole is inferior to fluconazole.

38
Q

What is the maintenance therapy for cryptococcal disease?

A

Fluconazole 200 mg per day until at least 1 year from initiation of antifungal treatment

This helps prevent recurrence of the disease.

39
Q

True or False: Echinocandins are recommended for the clinical management of cryptococcosis.

A

False

Echinocandins have no clinical activity against Cryptococcus spp.

40
Q

What should be monitored closely when using flucytosine?

A

Therapeutic drug monitoring, particularly in patients with renal impairment

Serum peak concentrations should be between 25 mg/L and 100 mg/L.

41
Q

What is the significance of CSF culture results after induction therapy?

A

Successful induction is defined by substantial clinical improvement and a negative CSF culture

Positive CSF CrAg may not indicate treatment failure at Week 2.

42
Q

What is the recommended initial management for cryptococcosis?

A

Posaconazole, voriconazole, and isavuconazole are not recommended for initial management or maintenance therapy

Echinocandins have no clinical activity against Cryptococcus spp. and are not recommended.

43
Q

What is the maintenance therapy for cryptococcosis?

A

Fluconazole 200 mg per day for at least 1 year from initiation of antifungal therapy

Assumes immune reconstitution on ART and patient is asymptomatic.

44
Q

How should non-CNS extrapulmonary cryptococcosis be treated?

A

Same as CNS disease

Mild symptoms with focal pulmonary infiltrates may be treated with fluconazole 400 mg per day for 6 to 12 months.

45
Q

What should be done for patients with non-CNS extrapulmonary symptoms and cryptococcal antigenemia?

A

CSF should be sampled to rule out CNS disease

If serum CrAg titer is ≥1:640, treat as patients with cryptococcal meningitis.

46
Q

When should CSF be sampled in patients with asymptomatic cryptococcal antigenemia?

A

Dependent on underlying risk and serum CrAg titer

Lower risk patients with serum CrAg <1:80 can be treated without lumbar puncture.

47
Q

What is the recommended fluconazole regimen for fully asymptomatic cryptococcal antigenemia?

A

Fluconazole 800 to 1,200 mg per day for 2 weeks, followed by 400 to 800 mg per day for 10 weeks, then 200 mg daily for a total of 6 months

Should be combined with effective ART.

48
Q

When should ART be initiated in patients with CNS cryptococcosis?

A

Generally deferred for 4 to 6 weeks after starting antifungal therapy

Early ART can increase mortality in some cases.

49
Q

What was the outcome of the trial comparing early versus delayed ART initiation?

A

Greater increase in 6-month mortality in the early ART group (45% vs. 30%)

Most pronounced in the first 8 to 30 days.

50
Q

What is the recommended approach for ART initiation in patients with non-CNS cryptococcosis?

A

Delay ART initiation for 2 weeks after starting antifungal therapy

Risk of symptomatic IRIS appears to be lower.

51
Q

What are common side effects of higher dose fluconazole therapy?

A

Dry skin (17%), alopecia (16%)

Increased liver transaminases are rare at doses of 400 to 800 mg.

52
Q

What is the risk of IRIS in patients with cryptococcal meningitis after starting ART?

A

10 to 30% may experience IRIS

Both unmasking and paradoxical IRIS may occur.

53
Q

How can the risk of IRIS be minimized in patients with cryptococcal meningitis?

A

Achieving CSF culture sterility before starting ART and deferring ART initiation for 4 to 6 weeks

Using fluconazole 800 mg per day as consolidation therapy also helps.

54
Q

What is the management strategy for IRIS?

A

Continue both ART and antifungal therapy, reduce elevated ICP if present

Difficult to distinguish IRIS from treatment failure.

55
Q

What should be done if a patient’s CSF opening pressure is ≥25 cm CSF?

A

Immediate clinical intervention to reduce ICP is required

Increased ICP is associated with high mortality rates.

56
Q

What is recommended for initial management of elevated ICP in cryptococcal meningitis?

A

Drainage of CSF via lumbar puncture

Aim to reduce opening pressure by at least 50%.

57
Q

What are the recommendations for therapeutic lumbar punctures in cryptococcal meningitis?

A

Repeat daily until symptoms improve and opening pressure normalizes to <20 cm CSF

Strong consideration for repeating within 72 hours if initial pressure was <25 cm CSF.

58
Q

What should be monitored in patients treated with amphotericin B?

A

Nephrotoxicity and electrolyte disturbances

Pre-infusion saline administration reduces nephrotoxicity risk.

59
Q

What are the side effects associated with flucytosine?

A

Concentration-dependent bone marrow toxicity, hepatotoxicity, gastrointestinal toxicities

Monitoring is necessary for dosage adjustments.

60
Q

What should be done for patients experiencing amphotericin B infusion reactions?

A

Administer acetaminophen and diphenhydramine or hydrocortisone before infusion

Meperidine can be used for amphotericin B–associated rigors.

61
Q

What does a negative PCR test indicate in the context of CSF cultures?

A

A negative PCR test has a high predictive value for sterile CSF cultures and can help distinguish between paradoxical IRIS and culture-positive relapse.

62
Q

What is the recommended management strategy for IRIS?

A

Continue both ART and antifungal therapy, reduce elevated ICP, and consider escalating antifungal therapy.

63
Q

What corticosteroid dosage is commonly recommended for severe symptoms of IRIS?

A

Starting at 1.0 mg/kg per day of prednisone.

64
Q

What does elevated serum C-reactive protein (CRP) indicate at the time of IRIS development?

A

CRP is generally elevated and will decrease with corticosteroid therapy if IRIS is present.

65
Q

How does the risk of IRIS differ among various forms of cryptococcosis?

A

The risk of IRIS is much lower and less severe with forms like lymphadenitis, cutaneous abscesses, and bony lesions compared to cryptococcal meningitis.

66
Q

Define treatment failure in the context of cryptococcal therapy.

A

Treatment failure is defined by lack of clinical improvement and continued positive cultures after 2 weeks of therapy or relapse after initial clinical response.

67
Q

What should be done if treatment failure or relapse occurs with Cryptococcus?

A

Cryptococcus isolates should undergo antifungal susceptibility testing.

68
Q

What is the preferred regimen for patients with treatment failure after induction?

A

Start preferred regimens or continue amphotericin B until clinical response occurs.

69
Q

What is the recommended outpatient consolidation therapy after achieving CSF sterility?

A

Fluconazole at a higher dose of 1,200 mg per day and optimization of ART.

70
Q

What is the recommended chronic maintenance therapy after completing induction for cryptococcal meningitis?

A

Fluconazole 200 mg per day for at least 1 year.

71
Q

When can maintenance therapy for cryptococcosis be discontinued?

A

After at least 1 year from initiation if CD4 counts are ≥100 cells/mm3 with undetectable viral loads.

72
Q

What is the risk associated with fluconazole use during the first trimester of pregnancy?

A

Fluconazole has teratogenic potential and may lead to congenital malformations.

73
Q

What should be the approach for pregnant individuals with cryptococcal infections?

A

Treatment should be initiated promptly, with attention to management of increased ICP.

74
Q

What is the recommendation regarding ART initiation in pregnant individuals with CNS cryptococcal infection?

A

Start ART as expeditiously as possible to reduce the risk of perinatal transmission of HIV.

75
Q

What is the preferred therapy for cryptococcosis in the first trimester of pregnancy?

A

Amphotericin B deoxycholate is preferred and has not been associated with teratogenicity.

76
Q

What should be considered when using flucytosine during pregnancy?

A

Flucytosine should be delayed until after the first trimester when feasible due to teratogenic potential.

77
Q

What is the recommendation regarding azole antifungals during the first trimester of pregnancy?

A

Azole antifungals should generally be avoided unless the benefits outweigh the risks.

78
Q

What findings have been reported regarding fluconazole exposure during pregnancy?

A

Increased prevalence of heart defects and other congenital malformations.

79
Q

What is the recommendation for switching to oral fluconazole after the first trimester?

A

Switching to oral fluconazole may be considered if appropriate clinically for consolidation or maintenance therapy.

80
Q

What is the conclusion about itraconazole exposure during pregnancy?

A

No significant difference in overall risk of birth defects compared to non-exposed groups.

81
Q

What is the recommendation for voriconazole, posaconazole, and isavuconazole during pregnancy?

A

They are not recommended, especially in the first trimester.